Terms: = Kidney tumors AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Treatment
61 results:
1. Does depressurization of the portal vein before liver transplantation affect the recurrence of HCC? A nested case-control study.
Wei G; Zhao Y; Feng S; Yuan J; Xu G; Lv T; Yang J; Kong L; Yang J
BMC Cancer; 2024 May; 24(1):558. PubMed ID: 38702621
[TBL] [Abstract] [Full Text] [Related]
2. Postoperative outcomes of transperitoneal versus retroperitoneal robotic partial nephrectomy: a propensity-score matched comparison focused on patient mobilization, return to bowel function, and pain.
Bertolo R; Ditonno F; Veccia A; De Marco V; Migliorini F; Porcaro AB; Rizzetto R; Cerruto MA; Autorino R; Antonelli A;
J Robot Surg; 2024 Feb; 18(1):96. PubMed ID: 38413473
[TBL] [Abstract] [Full Text] [Related]
3. The Value of Dual-Energy Computed Tomography-Based Radiomics in the Evaluation of Interstitial Fibers of Clear Cell Renal Carcinoma.
Bing X; Wang N; Li Y; Sun H; Yao J; Li R; Li Z; Ouyang A
Technol Cancer Res Treat; 2024; 23():15330338241235554. PubMed ID: 38404055
[TBL] [Abstract] [Full Text] [Related]
4. Multiple factors influence decision making for the surgical treatment in patients with renal cell carcinoma.
Kröger Dahlin BI; Hlodan J; Ghaffarpour R; Ljungberg B
Scand J Urol; 2024 Feb; 59():26-30. PubMed ID: 38358280
[TBL] [Abstract] [Full Text] [Related]
5. Stereotactic radiosurgery of brain metastases: a retrospective study.
Gruber I; Weidner K; Treutwein M; Koelbl O
Radiat Oncol; 2023 Dec; 18(1):202. PubMed ID: 38115009
[TBL] [Abstract] [Full Text] [Related]
6. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
[TBL] [Abstract] [Full Text] [Related]
7. Identification and validation of ubiquitin-proteasome system related genes as a prognostic signature for papillary renal cell carcinoma.
Zhang X; Liu X; Xiong R; An HX
Aging (Albany NY); 2022 Nov; 14(23):9599-9616. PubMed ID: 36385010
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of long-term renal function in patients with malignant solid tumors: Retrospective analysis using the estimated glomerular filtration rate.
Sano H; Kobayashi R; Matsushima S; Hori D; Yanagi M; Kodama K; Suzuki D; Kobayashi K
Pediatr Int; 2022 Jan; 64(1):e15373. PubMed ID: 36176204
[TBL] [Abstract] [Full Text] [Related]
9. Sociodemographic factors associated with Wilms tumor treatment and survival: a population-based study.
Bhambhvani HP; Peterson DJ; Sheth KR
Int Urol Nephrol; 2022 Dec; 54(12):3055-3062. PubMed ID: 36069962
[TBL] [Abstract] [Full Text] [Related]
10. [IL-1β inhibitor sensitizes to olaparib in homologous recombination deficiency proficient ovarian cancer cells].
Xu JF; Cen YX; Tang SS; Ren Y; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2022 Jul; 57(7):519-529. PubMed ID: 35902786
[No Abstract] [Full Text] [Related]
11. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract] [Full Text] [Related]
12. Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting.
Huang MM; Alam R; Gabrielson AT; Su ZT; Kassiri B; Fletcher SA; Biles MJ; Patel HD; Pavlovich CP; Schwen ZR
Eur Urol Focus; 2022 Sep; 8(5):1141-1150. PubMed ID: 34344628
[TBL] [Abstract] [Full Text] [Related]
13. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
[No Abstract] [Full Text] [Related]
14. The effect of microRNA-330 replacement on inhibition of growth and migration in renal cancer cells.
Liu J; Song X; Ren Z
Biotechnol Appl Biochem; 2022 Apr; 69(2):558-566. PubMed ID: 33605482
[TBL] [Abstract] [Full Text] [Related]
15. Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review.
Gamulin M; Nham E; Rkman D; Antunac Golubić Z; Likić R
Croat Med J; 2020 Aug; 61(4):326-332. PubMed ID: 32881430
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.
Tannir NM; Signoretti S; Choueiri TK; McDermott DF; Motzer RJ; Flaifel A; Pignon JC; Ficial M; Frontera OA; George S; Powles T; Donskov F; Harrison MR; Barthélémy P; Tykodi SS; Kocsis J; Ravaud A; Rodriguez-Cid JR; Pal SK; Murad AM; Ishii Y; Saggi SS; McHenry MB; Rini BI
Clin Cancer Res; 2021 Jan; 27(1):78-86. PubMed ID: 32873572
[TBL] [Abstract] [Full Text] [Related]
17. Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Okita K; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2021 Mar; 39(3):191.e9-191.e16. PubMed ID: 32713622
[TBL] [Abstract] [Full Text] [Related]
18. [Surgical treatment of intracaval tumor relapse after radical tumor nephrectomy in locally advanced renal cell carcinoma].
von Zehmen T; Eich C; Fries J; von Brandenstein M; Pfister D; Heidenreich A
Urologe A; 2020 Oct; 59(10):1217-1224. PubMed ID: 32514706
[TBL] [Abstract] [Full Text] [Related]
19. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
[TBL] [Abstract] [Full Text] [Related]
20. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
[No Abstract] [Full Text] [Related]
[Next]
